Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Purpose
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
Conditions
- Castration Levels of Testosterone
- Metastatic Prostatic Adenocarcinoma
- Stage IV Prostate Cancer AJCC v8
- Stage IVA Prostate Cancer AJCC v8
- Stage IVB Prostate Cancer AJCC v8
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- Male
- Accepts Healthy Volunteers
- No
Criteria
Inclusion Criteria:
- STEP 1 REGISTRATION: DISEASE-RELATED CRITERIA: All patients must have a
histologically or cytologically proven diagnosis of adenocarcinoma of the prostate.
Patients with pure small cell carcinoma* (SCC), sarcomatoid, or squamous cell
carcinoma are not eligible. (*morphology must be consistent with SCC; synaptophysin
or chromogranin positive by immunohistochemical staining is insufficient to diagnose
SCC).
- STEP 1 REGISTRATION: DISEASE-RELATED CRITERIA: Patients must have an intact
prostate. No prior local therapy for prostate adenocarcinoma is allowed (e.g.,
brachytherapy, high-intensity focused ultrasound [HIFU], cryotherapy, laser ablative
therapies). Any prior therapy for benign conditions, such as obstruction, are
acceptable (e.g., transurethral resection of the prostate, greenlight laser
ablation, microwave ablation).
- STEP 1 REGISTRATION: DISEASE-RELATED CRITERIA: Patients must have evidence of
metastatic disease on technetium bone scan and computed tomography (CT) or magnetic
resonance imaging (MRI) within 42 days prior to starting standard systemic therapy.
Metastatic disease that is detected by positron emission tomography (PET) scan only
(sodium fluoride [NaF], prostate-specific membrane antigen [PSMA],
anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid [FACBC], carbon [C]11) but
not conventional imaging (technetium [Tc]99 bone scan, CT or MRI) or solitary
metastases by conventional imaging, must be confirmed histologically or
cytologically.
- STEP 1 REGISTRATION: DISEASE-RELATED CRITERIA: Patients with known brain metastases
are not eligible. Brain imaging studies are not required for eligibility if the
patient has no neurologic signs or symptoms suggestive of brain metastasis. If brain
imaging studies are performed, they must be negative for disease.
- STEP 1 REGISTRATION: PRIOR/CONCURRENT THERAPY CRITERIA: Patients must have received
no more than 28 weeks of standard systemic therapy (SST). SST is defined as current
National Comprehensive Cancer Network (NCCN) guidelines for metastatic prostate
cancer.
- STEP 1 REGISTRATION: PRIOR/CONCURRENT THERAPY CRITERIA: Patients must not have
progressed while on SST.
- STEP 1 REGISTRATION: PRIOR/CONCURRENT THERAPY CRITERIA: Patients with
oligometastatic prostate cancer may receive metastasis directed therapy to up to
four sites of disease prior to randomization.
- STEP 1 REGISTRATION: CLINICAL/LABORATORY CRITERIA: Patients must have a complete
physical examination and medical history within 28 days prior to registration.
- STEP 1 REGISTRATION: CLINICAL/LABORATORY CRITERIA: Patients must have a PSA
documented prior to initiation of SST and within 28 days prior to registration. Any
additional PSAs measured while receiving SST should be recorded.
- STEP 1 REGISTRATION: CLINICAL/LABORATORY CRITERIA: Patients must have a testosterone
lab documented within 28 days prior to randomization. Any additional testosterone
labs measured while receiving SST should be recorded as well as pretreatment
initiation if available.
- STEP 1 REGISTRATION: CLINICAL/LABORATORY CRITERIA: No other prior malignancy is
allowed except for the following: adequately treated basal cell or squamous cell
skin cancer, adequately treated stage 0, I or II cancer from which the patient is
currently in complete remission, or any other cancer from which the patient has been
disease free for three years.
- STEP 1 REGISTRATION: SPECIMEN SUBMISSION CRITERIA: Patients must be offered the
opportunity to participate in translational medicine studies and specimen banking
for future studies.
- STEP 1 REGISTRATION: QUALITY OF LIFE CRITERIA: Patients who can complete
Patient-Reported Outcome instruments in English, Spanish or French, must participate
in the quality of life studies.
- STEP 1 REGISTRATION: REGULATORY CRITERIA: Patients must be informed of the
investigational nature of this study and must sign and give written informed consent
in accordance with institutional and federal guidelines.
- STEP 2 RANDOMIZATION: DISEASE-RELATED CRITERIA: As a part of the OPEN registration
process the treating institution's identity is provided in order to ensure that the
current (within 365 days) date of institutional review board approval for this study
has been entered in the system.
- STEP 2 RANDOMIZATION: DISEASE-RELATED CRITERIA: Patients must have no evidence of
disease progression during the 28 weeks of SST by PSA measure, bone scan and CT or
MRI or symptomatic deterioration (as defined by physician discretion) within 28 days
prior to randomization.
- STEP 2 RANDOMIZATION: DISEASE-RELATED CRITERIA: Patients must have consultation with
a urologist and have surgically resectable disease regardless of definitive
treatment intent or randomization.
- STEP 2 RANDOMIZATION: PRIOR/CONCURRENT THERAPY CRITERIA: Patients must have received
between 22 and 28 weeks of SST as measured from the date of first hormonal therapy
or surgical castration. SST is defined by current NCCN guidelines for metastatic
prostate cancer.
- STEP 2 RANDOMIZATION: PRIOR/CONCURRENT THERAPY CRITERIA: Patients must not be
planning to receive docetaxel after randomization.
- STEP 2 RANDOMIZATION: PRIOR/CONCURRENT THERAPY CRITERIA: Any toxicities from SST
must have resolved to =< grade 1 (Common Terminology Criteria for Adverse Events
[CTCAE] version 5.0) prior to randomization.
- STEP 2 RANDOMIZATION: PRIOR/CONCURRENT THERAPY CRITERIA: Patients may have received
elective metastasis directed therapy to oligometastatic sites (=< 4 sites). All
treatment must be completed prior to randomization.
- STEP 2 RANDOMIZATION: CLINICAL/LABORATORY CRITERIA: Patients must have a PSA
performed within 28 days prior to randomization.
- STEP 2 RANDOMIZATION: CLINICAL/LABORATORY CRITERIA: Patients must have a
testosterone < 50 ng/dL within 28 days prior to randomization.
- STEP 2 RANDOMIZATION: CLINICAL/LABORATORY CRITERIA: Patients must have a Zubrod
performance status of 0 ? 1 within 28 days prior to randomization.
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Active Comparator Arm I (SST) |
Participants receive 1 acceptable form of SST as in Induction except for treatment with docetaxel and prednisone. |
|
|
Experimental Arm II (SST, prostatectomy or radiation therapy) |
Participants receive 1 acceptable form of SST as in Induction except for treatment with docetaxel and prednisone. Participants undergo prostatectomy within 8 weeks after randomization or radiation therapy within 4 weeks of randomization. |
|
|
Active Comparator Step 1 (pre-randomization) |
Standard treatment data collection prior to randomization |
|
Recruiting Locations
Gilbert, Arizona 85234
Site Public Contact
602-747-9738
Phoenix, Arizona 85004
Tucson, Arizona 85704
Site Public Contact
520-694-8900
Tucson, Arizona 85719
Little Rock, Arkansas 72205
Site Public Contact
501-686-8274
Antioch, California 94531
Clovis, California 93611
Site Public Contact
559-387-1827
Duarte, California 91010
Dublin, California 94568
Site Public Contact
877-642-4691
Fremont, California 94538
Fresno, California 93720
Fresno, California 93720
La Jolla, California 92093
Long Beach, California 90822
Site Public Contact
562-826-8000
Los Angeles, California 90033
Site Public Contact
323-865-0451
Los Angeles, California 90033
Site Public Contact
323-865-0451
Marysville, California 95901
Site Public Contact
530-749-4400
Modesto, California 95356
Oakland, California 94611
Oakland, California 94611
Palm Springs, California 92262
Site Public Contact
760-416-4730
Palo Alto, California 94304
Rancho Cordova, California 95670
Redwood City, California 94063
Richmond, California 94801
Rohnert Park, California 94928
Roseville, California 95661
Roseville, California 95678
Sacramento, California 95814
Sacramento, California 95816
Sacramento, California 95817
Site Public Contact
916-734-3089
Sacramento, California 95823
Sacramento, California 95823
San Francisco, California 94115
San Jose, California 95119
San Leandro, California 94577
San Luis Obispo, California 93401
San Rafael, California 94903
Santa Clara, California 95051
Santa Rosa, California 95403
South San Francisco, California 94080
South San Francisco, California 94080
Stockton, California 95210
Truckee, California 96161
Site Public Contact
530-582-6450
Vacaville, California 95688
Vallejo, California 94589
Walnut Creek, California 94596
Aurora, Colorado 80045
Site Public Contact
720-848-0650
Boulder, Colorado 80304
Colorado Springs, Colorado 80909
Site Public Contact
719-365-2406
Colorado Springs, Colorado 80920
Site Public Contact
719-364-6700
Denver, Colorado 80210
Edwards, Colorado 81632
Site Public Contact
970-569-7429
Fort Collins, Colorado 80524
Site Public Contact
970-297-6150
Greeley, Colorado 80631
Littleton, Colorado 80122
Loveland, Colorado 80539
Parker, Colorado 80138
Guilford, Connecticut 06437
New Haven, Connecticut 06520
Stamford, Connecticut 06904
Site Public Contact
203-323-8944
Trumbull, Connecticut 06611
Waterford, Connecticut 06385
West Haven, Connecticut 06516
Site Public Contact
203-937-3421
Newark, Delaware 19713
Newark, Delaware 19718
Washington, District of Columbia 20037
Site Public Contact
202-741-2981
Aventura, Florida 33180
Coral Gables, Florida 33146
Site Public Contact
305-243-2647
Deerfield Beach, Florida 33442
Site Public Contact
305-243-2647
Jacksonville, Florida 32207
Site Public Contact
904-202-7468
Miami Beach, Florida 33140
Miami, Florida 33136
Site Public Contact
305-243-2647
Miami, Florida 33176
Site Public Contact
305-243-2647
Plantation, Florida 33324
Site Public Contact
305-243-2647
Atlanta, Georgia 30303
Site Public Contact
404-489-9164
Atlanta, Georgia 30308
Site Public Contact
888-946-7447
Atlanta, Georgia 30322
Site Public Contact
404-778-1868
Atlanta, Georgia 30342
Site Public Contact
404-851-7115
Augusta, Georgia 30912
Decatur, Georgia 30033
Site Public Contact
404-321-6111
Caldwell, Idaho 83605
Nampa, Idaho 83687
Post Falls, Idaho 83854
Aurora, Illinois 60504
Bloomington, Illinois 61704
Canton, Illinois 61520
Carthage, Illinois 62321
Chicago, Illinois 60612
Chicago, Illinois 60612
Site Public Contact
312-355-3046
Decatur, Illinois 62526
Effingham, Illinois 62401
Eureka, Illinois 61530
Galesburg, Illinois 61401
Kewanee, Illinois 61443
Macomb, Illinois 61455
Maywood, Illinois 60153
Site Public Contact
708-226-4357
Ottawa, Illinois 61350
Pekin, Illinois 61554
Peoria, Illinois 61615
Peoria, Illinois 61636
Peoria, Illinois 61637
Peru, Illinois 61354
Princeton, Illinois 61356
Urbana, Illinois 61801
Richmond, Indiana 47374
Ames, Iowa 50010
Des Moines, Iowa 50309
Site Public Contact
515-241-6727
Iowa City, Iowa 52242
Site Public Contact
800-237-1225
Kansas City, Kansas 66160
Olathe, Kansas 66061
Overland Park, Kansas 66210
Westwood, Kansas 66205
Lexington, Kentucky 40504
Lexington, Kentucky 40509
Louisville, Kentucky 40202
Site Public Contact
502-562-3429
Metairie, Louisiana 70006
Metairie, Louisiana 70006
Bath, Maine 04530
Brewer, Maine 04412
Site Public Contact
800-987-3005
Portland, Maine 04102
Site Public Contact
207-885-7565
Sanford, Maine 04073
Site Public Contact
207-459-1600
Sanford, Maine 04073
Scarborough, Maine 04074
Ann Arbor, Michigan 48106
Ann Arbor, Michigan 48109
Site Public Contact
800-865-1125
Brighton, Michigan 48114
Brownstown, Michigan 48183
Canton, Michigan 48188
Chelsea, Michigan 48118
Clarkston, Michigan 48346
Clinton Township, Michigan 48038
Detroit, Michigan 48201
Detroit, Michigan 48202
Farmington Hills, Michigan 48334
Grand Rapids, Michigan 49503
Kalamazoo, Michigan 49007
Lansing, Michigan 48912
Site Public Contact
517-364-9400
Macomb, Michigan 48044
Madison Heights, Michigan 48071
Pontiac, Michigan 48341
Saginaw, Michigan 48601
Traverse City, Michigan 49684
Troy, Michigan 48098
West Bloomfield, Michigan 48322
Coon Rapids, Minnesota 55433
Edina, Minnesota 55435
Fridley, Minnesota 55432
Minneapolis, Minnesota 55415
Minneapolis, Minnesota 55454
Robbinsdale, Minnesota 55422
Saint Louis Park, Minnesota 55416
Saint Paul, Minnesota 55101
Shakopee, Minnesota 55379
Cape Girardeau, Missouri 63703
Cape Girardeau, Missouri 63703
Site Public Contact
573-651-5550
Columbia, Missouri 65212
Site Public Contact
573-882-7440
Creve Coeur, Missouri 63141
Joplin, Missouri 64804
Kansas City, Missouri 64154
Rolla, Missouri 65401
Saint Louis, Missouri 63110
Saint Louis, Missouri 63129
Saint Louis, Missouri 63131
Site Public Contact
314-996-5569
Saint Louis, Missouri 63136
Saint Louis, Missouri 63141
Site Public Contact
314-251-7066
Saint Peters, Missouri 63376
Sainte Genevieve, Missouri 63670
Site Public Contact
314-996-5569
Springfield, Missouri 65804
Site Public Contact
417-269-4520
Springfield, Missouri 65807
Site Public Contact
417-269-4520
Billings, Montana 59101
Bozeman, Montana 59715
Butte, Montana 59701
Site Public Contact
406-723-2621
Great Falls, Montana 59405
Kalispell, Montana 59901
Bellevue, Nebraska 68123
Omaha, Nebraska 68114
Site Public Contact
402-354-5144
Omaha, Nebraska 68118
Site Public Contact
402-559-5600
Omaha, Nebraska 68198
Henderson, Nevada 89052
Las Vegas, Nevada 89106
Las Vegas, Nevada 89128
Las Vegas, Nevada 89144
Las Vegas, Nevada 89148
Las Vegas, Nevada 89169
Concord, New Hampshire 03301
Site Public Contact
603-224-2556
Lebanon, New Hampshire 03756
Manchester, New Hampshire 03103
Site Public Contact
800-339-6484
Hackensack, New Jersey 07601
Site Public Contact
201-996-2879
Albany, New York 12208
Site Public Contact
518-262-5513
Bronx, New York 10461
Bronx, New York 10467
Buffalo, New York 14263
Dansville, New York 14437
Glens Falls, New York 12801
Site Public Contact
518-926-6700
New York, New York 10065
Site Public Contact
212-746-1848
Oneida, New York 13421
Oswego, New York 13126
Rochester, New York 14620
Site Public Contact
585-341-8113
Rochester, New York 14642
Site Public Contact
585-275-5830
Stony Brook, New York 11794
Site Public Contact
800-862-2215
Syracuse, New York 13210
Site Public Contact
315-464-5476
Albemarle, North Carolina 28002
Site Public Contact
800-804-9376
Charlotte, North Carolina 28203
Site Public Contact
800-804-9376
Charlotte, North Carolina 28210
Site Public Contact
980-442-2000
Charlotte, North Carolina 28262
Site Public Contact
800-804-9376
Charlotte, North Carolina 28277
Site Public Contact
800-804-9376
Concord, North Carolina 28025
Site Public Contact
800-804-9376
Gastonia, North Carolina 28054
Site Public Contact
800-804-9376
Hendersonville, North Carolina 28791
Monroe, North Carolina 28112
Site Public Contact
980-442-2000
New Bern, North Carolina 28561
Canton, Ohio 44708
Site Public Contact
888-293-4673
Centerville, Ohio 45459
Cincinnati, Ohio 45219
Cleveland, Ohio 44109
Columbus, Ohio 43210
Dayton, Ohio 45415
Kettering, Ohio 45409
Kettering, Ohio 45429
Sylvania, Ohio 43560
Toledo, Ohio 43606
West Chester, Ohio 45069
Oklahoma City, Oklahoma 73104
Chambersburg, Pennsylvania 17201
Danville, Pennsylvania 17822
Ephrata, Pennsylvania 17522
Site Public Contact
717-721-4840
Gettysburg, Pennsylvania 17325
Site Public Contact
877-441-7957
Lebanon, Pennsylvania 17042
Lewisburg, Pennsylvania 17837
Pittsburgh, Pennsylvania 15232
Site Public Contact
412-647-8073
Pittsburgh, Pennsylvania 15232
Site Public Contact
412-621-2334
Wilkes-Barre, Pennsylvania 18711
York, Pennsylvania 17403
Site Public Contact
877-441-7957
Boiling Springs, South Carolina 29316
Site Public Contact
864-241-6251
Charleston, South Carolina 29425
Greenville, South Carolina 29605
Site Public Contact
864-241-6251
Greenville, South Carolina 29607
Greenville, South Carolina 29615
Site Public Contact
864-241-6251
Greer, South Carolina 29650
Site Public Contact
864-241-6251
Myrtle Beach, South Carolina 29577
Site Public Contact
877-460-2657
Rock Hill, South Carolina 29730
Site Public Contact
800-804-9376
Rock Hill, South Carolina 29732
Site Public Contact
800-804-9376
Seneca, South Carolina 29672
Site Public Contact
864-241-6251
Nashville, Tennessee 37232
Site Public Contact
800-811-8480
Conroe, Texas 77384
Dallas, Texas 75235
Dallas, Texas 75237
Dallas, Texas 75390
Fort Worth, Texas 76104
Houston, Texas 77026-1967
Site Public Contact
713-566-5000
Houston, Texas 77030
Houston, Texas 77030
Site Public Contact
713-873-2000
Houston, Texas 77030
Houston, Texas 77030
Site Public Contact
800-553-2278
Houston, Texas 77079
League City, Texas 77573
Richardson, Texas 75080
San Antonio, Texas 78229
Site Public Contact
877-469-5300
Sugar Land, Texas 77478
Salt Lake City, Utah 84106
Salt Lake City, Utah 84112
Salt Lake City, Utah 84148
Site Public Contact
801-582-1565
Berlin, Vermont 05602
Site Public Contact
802-225-5400
Burlington, Vermont 05401
Midlothian, Virginia 23114
Richmond, Virginia 23230
Richmond, Virginia 23235
Richmond, Virginia 23298
South Hill, Virginia 23970
Bellevue, Washington 98004
Site Public Contact
425-454-2148
Kirkland, Washington 98034
Site Public Contact
425-899-6000
Seattle, Washington 98109
Site Public Contact
800-804-8824
Seattle, Washington 98133
Site Public Contact
206-606-5800
Seattle, Washington 98195
Site Public Contact
800-804-8824
Morgantown, West Virginia 26506
Antigo, Wisconsin 54409
Eau Claire, Wisconsin 54701
Marshfield, Wisconsin 54449
Menomonee Falls, Wisconsin 53051
Site Public Contact
262-257-5100
Milwaukee, Wisconsin 53226
Site Public Contact
414-805-3666
Milwaukee, Wisconsin 53295
Site Public Contact
888-469-6614
Minocqua, Wisconsin 54548
New Richmond, Wisconsin 54017
Oak Creek, Wisconsin 53154
Site Public Contact
414-805-0505
Rice Lake, Wisconsin 54868
Stevens Point, Wisconsin 54481
Stevens Point, Wisconsin 54482
Wausau, Wisconsin 54401
Site Public Contact
877-405-6866
West Bend, Wisconsin 53095
Site Public Contact
414-805-0505
Weston, Wisconsin 54476
Weston, Wisconsin 54476
Wisconsin Rapids, Wisconsin 54494
Site Public Contact
715-422-7718
More Details
- NCT ID
- NCT03678025
- Status
- Recruiting
- Sponsor
- SWOG Cancer Research Network
Detailed Description
PRIMARY OBJECTIVES: I. To compare overall survival in metastatic prostate cancer patients who are randomized to standard systemic therapy (SST) plus definitive treatment of the primary tumor versus standard systemic therapy alone. SECONDARY OBJECTIVES: I. To compare overall survival in metastatic prostate cancer patients who received SST plus surgical excision of the primary tumor versus SST alone in the subset who specify the surgical intent stratification factor. II. To compare the rate of symptomatic local progression between the treatment arms. III. To compare progression-free survival (PFS) between the two treatment arms. IV. To compare rates of progression-free survival between arms for the subsets of patients with and without metastasis directed therapy (MDT) to oligometastatic sites. QUALITY OF LIFE OBJECTIVES: I. To compare between arms patient-reported urinary function and urinary bother over time (after initiation of SST at 6 months, 1, 2, and 3 years) using the Expanded Prostate Cancer Index Composite (EPIC) and patient-reported pain and physical functioning using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) between patients receiving standard systemic therapy and those receiving systemic therapy and definitive management of the primary prostate cancer. OTHER OBJECTIVES: I. To bank tissue and whole blood specimens for future use. OUTLINE: INDUCTION: Participants receive 1 of 6 acceptable forms of SST for 22-28 weeks. I. Participants undergo a bilateral orchiectomy. II. Participants receive goserelin acetate subcutaneously (SC) every 28 days or 12 weeks, histrelin acetate SC every 12 months, leuprolide acetate SC or intramuscularly (IM) every 1, 3, 4, or 6 months, and triptorelin every 1, 3, or 6 months. III. Participants receive goserelin acetate SC every 28 days or 12 weeks, histrelin acetate SC every 12 months, leuprolide acetate SC or IM every 1, 3, 4, or 6 months, and triptorelin every 1, 3, or 6 months. Participants also receive nilutamide orally (PO) daily, flutamide PO every 8 hours, and bicalutamide PO daily. IV. Participants receive degarelix via injection for 2 doses and then every 28 days. V. Participants receive nilutamide PO daily, flutamide PO every 8 hours, and bicalutamide PO daily. Participants also receive docetaxel over 1 hour every 3 weeks with or without prednisone PO every 12 hours. VI. Participants receive nilutamide PO daily, flutamide PO every 8 hours, and bicalutamide PO daily. Participants also receive abiraterone PO daily or prednisone PO every 12 hours. After completion of 22-28 weeks of SST, participants are then randomized to 1 of 2 arms. ARM I: Participants receive 1 acceptable form of SST as in Induction except for treatment with docetaxel and prednisone. ARM II: Participants receive 1 acceptable form of SST as in Induction except for treatment with docetaxel and prednisone. Participants undergo prostatectomy within 8 weeks after randomization or radiation therapy within 4 weeks of randomization. After completion of study treatment, participants are followed up for 8 years.